Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women

Liu,Man; Xing,Lu‑Qi

doi:10.3892/ol.2017.6335

Basic fibroblast growth factor as a potential biomarker for diagnosing malignant tumor metastasis in women

Authors:
- Man Liu
- Lu‑Qi Xing
View Affiliations

Affiliations: Department of Pathology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
Published online on: June 7, 2017 https://doi.org/10.3892/ol.2017.6335
Pages: 1561-1567
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have reported that basic fibroblast growth factor (bFGF) is associated with tumor genesis, growth and prognosis. The present study was conducted to detect the levels of bFGF expression in women with non‑small cell lung cancer (NSCLC), colon cancer, breast cancer and melanoma, and analyze its association with the clinicopathological characteristics of malignant tumors. The tumor tissues were obtained from 508 female patients with malignant tumors between March 2008 and May 2015 (103 NSCLC, 147 colon cancer, 206 breast cancer and 52 melanoma). Histological examination was performed on paraffin‑embedded tissues. The immunohistochemical peroxidase‑conjugated streptavidin method was used to detect bFGF protein expression in the tissues. The level of bFGF protein expression was significantly increased in patients with NSCLC with poor differentiation and lymph node metastasis compared with patients with moderately/well differentiated NSCLC without lymph node metastasis. Increased levels of bFGF protein expression were observed in patients with colon cancer with lymph node metastasis compared with patients without lymph node metastasis, and in patients with breast cancer with tumor‑node‑metastasis stage III‑IV and lymph node metastasis compared with patients in stage I‑II and without lymph node metastasis. The rate of positive bFGF staining in patients with melanoma with lymph node metastasis was significantly higher compared with patients without lymph node metastasis. These results suggested that bFGF may be associated with the process of malignant tumor genesis and growth, and the expression of bFGF protein may be a potential and effective biomarker for diagnosing malignant tumor metastasis in females. The present study may also provide theoretical bases for the clinical application of bFGF monoclonal antibody in molecular targeted therapies in tumors.

View Figures

View References

1	Attoub S, Arafat K, Gélaude A, Al Sultan MA, Bracke M, Collin P, Takahashi T, Adrian TE and De Wever O: Frondoside a suppressive effects on lung cancer survival, tumor growth, angiogenesis, invasion, and metastasis. PLoS One. 8:e530872013. View Article : Google Scholar : PubMed/NCBI
2	Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK and Lee SD: Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol. 10:355–362. 2003. View Article : Google Scholar : PubMed/NCBI
3	Gospodarowicz D: Fibroblast growth factor. Chemical structure and biologic function. Clin Orthop Rel Res. 257:231–248. 1990.
4	Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, Doetschman T, Coffin JD and Hurley MM: Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest. 105:1085–1093. 2000. View Article : Google Scholar : PubMed/NCBI
5	Wei X: Research advances of basic fibroblast growth factor in tissue repair. Orthop J Chin. 19:1108–1110. 2011.
6	Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R and Rusnati M: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16:159–178. 2005. View Article : Google Scholar : PubMed/NCBI
7	Luo CF, Hong HL, Lu YL, Wang H and Liu MQ: Expression of bFGF and PTEN in cervical carcinoma and their clinical significance. Zhonghua Zhong Liu Za Zhi. 32:533–538. 2010.(In Chinese). PubMed/NCBI
8	Trojan L, Thomas D, Knoll T, Grobholz R, Alken P and Michel MS: Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer. Urol Res. 32:97–1031. 2004. View Article : Google Scholar : PubMed/NCBI
9	Cucina A, Borrelli V, Lucarelli M, Sterpetti AV, Cavallaro A, Strom R, Santoro-D'Angelo L and Scarpa S: Autocrine production of basic fibroblast growth factor translated from novel synthesized mRNA mediates thrombin-induced mitogenesis in smooth muscle cells. Cell Biochem Funct. 20:39–46. 2002. View Article : Google Scholar : PubMed/NCBI
10	Polnaszek N, Kwabi-Addo B, Peterson LE, Ozen M, Greenberg NM, Ortega S, Basilico C and Ittmann M: Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res. 63:5754–5760. 2003.PubMed/NCBI
11	Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW and Bunn PA Jr: Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res. 4:521–528. 2006. View Article : Google Scholar : PubMed/NCBI
12	Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, et al: Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol. 75:196–207. 2009. View Article : Google Scholar : PubMed/NCBI
13	Xu TM, Xin Y, Cui MH, Jiang X and Gu LP: Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. Chin Med J (Engl). 120:584–588. 2007.PubMed/NCBI
14	Sobin LH, Hermanek P and Hutter RV: TNM classification of malignant tumors. A comparison between the new (1987) and the old editions. Cancer. 61:2310–2314. 1988. View Article : Google Scholar : PubMed/NCBI
15	Song S, Wientjes MG, Gan Y and Au JL: Fibroblast growth factors: An epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA. 97:pp. 8658–8663. 2000; View Article : Google Scholar : PubMed/NCBI
16	Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M and Shibasaki M: YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin Cancer Res. 12:1630–1638. 2006. View Article : Google Scholar : PubMed/NCBI
17	Keegan K, Johnson DE, Williams LT and Hayman MJ: Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc Natl Acad Sci USA. 88:pp. 1095–1099. 1991; View Article : Google Scholar : PubMed/NCBI
18	Joensuu H, Anttonen A, Eriksson M, Mäkitaro R, Alfthan H, Kinnula V and Leppä S: Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res. 62:5210–5217. 2002.PubMed/NCBI
19	Elagoz S, Egilmez R, Koyuncu A, Muslehiddinoglu A and Arici S: The intratumoral microvessel density and expression of bFGF and nm23-H1 in colorectal cancer. Pathol Oncol Res. 12:21–27. 2006. View Article : Google Scholar : PubMed/NCBI
20	Landriscina M, Cassano A, Ratto C, Longo R, Ippoliti M, Palazzotti B, Crucitti F and Barone C: Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer. 78:765–770. 1998. View Article : Google Scholar : PubMed/NCBI
21	Faridi A, Rudlowski C, Biesterfeld S, Schuh S, Rath W and Schröder W: Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. Pathol Res Pract. 198:1–5. 2002. View Article : Google Scholar : PubMed/NCBI
22	Takeda M, Mikami T, Numata Y, Okamoto M and Okayasu I: Papillary thyroid carcinoma with heterotopic ossification is a special subtype with extensive progression. Am J Clin Pathol. 139:587–598. 2013. View Article : Google Scholar : PubMed/NCBI
23	Chikazawa M, Inoue K, Fukata S, Karashima T and Shuin T: Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiology. 75:335–345. 2008. View Article : Google Scholar : PubMed/NCBI
24	Straume O and Akslen LA: Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenetic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. Am J Pathol. 160:1009–1019. 2002. View Article : Google Scholar : PubMed/NCBI
25	Birck A, Kirkin AF, Zeuthen J and Hou-Jensen K: Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res. 9:375–381. 1999. View Article : Google Scholar : PubMed/NCBI